Changes in Sexual Risk Behavior Among Participants in a PrEP HIV Prevention Trial

被引:94
作者
Guest, Greg [1 ]
Shattuck, Dominick [1 ]
Johnson, Laura [1 ]
Akumatey, Betty [3 ]
Clarke, Edith Essie Kekawo
Chen, Pai-Lien [2 ]
MacQueen, Kathleen M. [1 ]
机构
[1] Family Hlth Int, Div Behav & Biomed Res, Res Triangle Pk, NC 27709 USA
[2] Family Hlth Int, Div Biostat, Res Triangle Pk, NC 27709 USA
[3] Univ Ghana, Dept Sociol, Legon, Ghana
关键词
D O I
10.1097/OLQ.0b013e3181812939
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: One of the concerns raised regarding the introduction of any new HIV-prevention measure, such as PrEP, is the potential for risk disinhibition or sexual risk compensation. The oral tenofovir HIV prevention trial has been the subject of international discussion in this regard. Methods: This article maps the changes in sexual risk behavior among women participating in the oral tenofovir HIV prevention trial in Ghana. Content-driven, thematic analysis was carried out on qualitative data obtained from in-depth interviews with study participants. Growth curve analysis was the primary method used to document trends over time in self-reported sexual behavior collected monthly. Results: Overall, the study found that sexual risk behavior did not increase during the trial. Number of sexual partners and rate of unprotected sex acts decreased across the 12-month period of study enrollment. Certain subgroups of women, however, exhibited different growth curves. Data indicate that the HIV prevention counseling associated with the trial was effective. Conclusions: Counseling during the trial was effective. Different types of counseling and messaging may be needed for different subgroups within a population. These findings also have implications for required sample sizes for future HIV prevention trials where seroconversion is the main outcome.
引用
收藏
页码:1002 / 1008
页数:7
相关论文
共 27 条
[1]  
ABIDJAN NC, 2005, VOA COM 0215
[2]   Trial of antiretroviral for HIV prevention on hold [J].
Ahmad, K .
LANCET INFECTIOUS DISEASES, 2004, 4 (10) :597-597
[3]   HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial [J].
Bartholow, BN ;
Buchbinder, S ;
Celum, C ;
Goli, V ;
Koblin, B ;
Para, M ;
Marmor, M ;
Novak, RM ;
Mayer, K ;
Creticos, C ;
Orozco-Cronin, P ;
Popovic, V ;
Mastro, TD .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (01) :90-101
[4]   PROPHYLACTIC VACCINES, RISK BEHAVIOR-CHANGE, AND THE PROBABILITY OF ERADICATING HIV IN SAN-FRANCISCO [J].
BLOWER, SM ;
MCLEAN, AR .
SCIENCE, 1994, 265 (5177) :1451-1454
[5]  
BONN D, 2004, LANCET INFECT DIS, V5, P78
[6]   HIV and risk behaviour - Risk compensation: the Achilles' heel of innovations in HIV prevention? [J].
Cassell, MM ;
Halperin, DT ;
Shelton, JD ;
Stanton, D .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7541) :605-607
[7]  
*CDCP, 2004, ANSWR AN SOFTW WORD
[8]   Risk behavior for HIV infection in participants in preventive HIV vaccine trials: A cautionary note [J].
Chesney, MA ;
Chambers, DB ;
Kahn, JO .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (04) :266-271
[9]  
DECHAMBENOIT G, 2005, AFR J NEUROL SCI, P24
[10]  
ELIAS P, 1914, SAN JOSE MERCUR 0704